Evidence map›Paper›PMID 30770968›Full record

ArticleEuropean radiology2019

Whole tumor ablation of locally recurred hepatocellular carcinoma including retained iodized oil after transarterial chemoembolization improves progression-free survival.

Dong Ho Lee, Jeong Min Lee, Pyo Nyun Kim, Yun-Jin Jang, Tae Wook Kang, Hyunchul Rhim, Jung Wook Seo, Young Joon Lee

Abstract readMulticenter Study
PubMed Publisher
In one paragraph

Article in European radiology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.2field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 6 institutions in 1 country.

Dong Ho Lee
Jeong Min LeeDepartment of Radiology, Seoul National University Hospital, 101 Daehangno, Jongno-gu, Seoul, 110-744, South Korea. jmsh@snu.ac.kr.
Pyo Nyun KimDepartment of Radiology and Research Institute of Radiology, University of Ulsan, Asan Medical Center, Seoul, South Korea.
Yun-Jin JangDepartment of Radiology and Research Institute of Radiology, University of Ulsan, Asan Medical Center, Seoul, South Korea.
Tae Wook KangDepartment of Radiology, Samsung Medical Center, School of Medicine, Sungkyunkwan University, Seoul, South Korea.
Hyunchul RhimDepartment of Radiology, Samsung Medical Center, School of Medicine, Sungkyunkwan University, Seoul, South Korea.
Jung Wook SeoDepartment of Radiology, Inje University Ilsan Paik Hospital, Goyang, South Korea.
Young Joon LeeDepartment of Radiology, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, South Korea.
Asan Medical Center · KRSamsung Medical Center · KRCatholic University of Korea · KRInje University Ilsan Paik Hospital · KRSeoul National University · KRSeoul National University Hospital · KR

Funding

Korean Society of Imaging-guided Tumor Ablation KSITA-201701
6 · The paper itself

Abstract

objectivesTo evaluate and compare clinical outcomes of two different radiofrequency ablation (RFA) methods for locally recurred hepatocellular carcinoma (LrHCC) after locoregional treatment.

methodsOur institutional review board approved this study with a waiver of informed consent. A total of 313 patients previously treated with transarterial chemoembolization (TACE) (n = 167) and RFA (n = 146) with a single LrHCC ≤ 3 cm was included from five tertiary referral hospitals. RFA was done for LrHCCs using either viable tumor alone ablation (VTA) method (VTA: n = 61 in the TACE group and n = 127 in the RFA group) or whole tumor ablation (WTA) method which includes both viable tumor and retained iodized oil or previously ablated zone (WTA: n = 106 in the TACE group and n = 19 in the RFA group). Local tumor progression (LTP)-free survival as well as progression-free survival (PFS) were estimated using the Kaplan-Meier method, and prognostic factors were evaluated using the Cox proportional hazards regression model.

resultsIn 167 patients with LrHCC who underwent TACE, the 5-year LTP-free survival after RFA was significantly higher with the VTA method than with the WTA method (26.9% vs. 87.8%; p < 0.001; hazard ratio (HR) = 8.53 [4.16-17.5]). The estimated 5-year PFS after RFA for LrHCC after TACE using the VTA method was 5.7%, which was significantly lower than that with the WTA method (26.4%) (p = 0.014; HR = 1.62 [1.10-2.38]). However, in 146 patients with LrHCC after initial RFA, there were no significant differences in cumulative incidence of LTP (p = 0.514) or PFS (p = 0.905) after RFA between the two ablation methods.

conclusionsFor RFA of LrHCC after TACE, the WTA method including both viable tumor and retained iodized oil could significantly lower LTP and improve PFS than VTA. KEY POINTS: • Whole tumor ablation (WTA) could provide significantly better local tumor control for locally recurred HCC (LrHCC) after TACE than viable tumor alone ablation (VTA). • WTA for LrHCC after TACE could also provide significantly better progression-free survival than VTA. • Regarding LrHCC after RFA, VTA would provide a comparable clinical outcome to WTA.

Indexed as

Ablation TechniquesAgedCarcinoma, HepatocellularChemoembolization, TherapeuticContrast MediaFemaleHumansIodized OilLiver NeoplasmsMaleMiddle AgedNeoplasm Recurrence, LocalProgression-Free SurvivalTomography, X-Ray ComputedTreatment OutcomeContrast MediaIodized OilAblation techniquesChemoembolizationHepatocellular carcinomaProgression-free survivalTherapeutic

Identifiers

PMID30770968
OpenAlexW2912221829

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.